Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 7/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPRB | P23467 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2556608 | 0.87 | MRGPRX4 (0.62) | MRGPRX4MAOBNR4A2MGLLMAPT | |
| SCHEMBL18550280 | 0.86 | MAOB (0.68) | MRGPRX4MAOBNR4A2MGLLMAPT | |
| SCHEMBL10335673 | 0.85 | MAOB (0.65) | MRGPRX4MAOBNR4A2PTPN2PTPN1 | |
| SCHEMBL12420271 | 0.82 | ENPP2 (0.54) | MAOB | |
| SCHEMBL5025938 | 0.82 | MRGPRX4 (0.69) | MRGPRX4MAOBNR4A2MAPTPOLB | |
| SCHEMBL16804808 | 0.81 | MAOB (0.62) | MRGPRX4MAOBNR4A2MAPTPTPN2 | |
| SCHEMBL18164441 | 0.81 | MAOB (0.57) | MRGPRX4MAOBNR4A2MAPTPOLB | |
| SCHEMBL11790839 | 0.81 | MRGPRX4 (0.57) | MRGPRX4MAOBNR4A2PTPN2PTPN1 | |
| SCHEMBL18164564 | 0.79 | MAOB (0.59) | MRGPRX4MAOBNR4A2MAPTHTT | |
| SCHEMBL18161388 | 0.79 | NR4A2 (0.60) | MRGPRX4MAOBNR4A2MAPTPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3285583-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| EP-3285583-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | The Regents of The University of Michigan (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9884841-B2 | Small molecule inhibitors of Mcl-1 and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-02-06 | — | — | US | disclosed |
| WO-2016172218-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160304485-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MRGPRX4 243/4885MAOB 780/4885NR4A2 754/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MRGPRX4 243/4885MAOB 780/4885NR4A2 754/4885 |
| US-20160304485-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | MCL1, BCL2L1, BCL2L11 | MRGPRX4 4127/4885MAOB 3535/4885NR4A2 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.